NASDAQ:AGEN Agenus Q2 2026 Earnings Results & Report $6.50 -0.45 (-6.47%) Closing price 10/14/2026 04:00 PM EasternExtended Trading$6.58 +0.08 (+1.23%) As of 04:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Agenus missed analyst earnings expectations but beat on revenue in its Q2 2026 results, released August 7, 2026. The company reported EPS of -$0.01 versus the $0.05 consensus estimate, while revenue of $34.52 million topped the $34.00 million estimate by $0.52 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 7, 2026TimeAfter Market ClosesConference Call DateAugust 6, 2026Conference Call9:30 AM ET Agenus EPS ResultsActual EPS-$0.01Consensus EPS $0.05Beat/MissMissed by -$0.06One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersAgenus Revenue ResultsActual Revenue$34.52 millionExpected Revenue$34.00 millionBeat/MissBeat by +$518.00 thousandYoY Revenue GrowthN/AUpcoming EarningsAgenus' Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 3, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Agenus Q2 2026 Earnings FAQ Did Agenus beat earnings estimates for Q2 2026? Agenus (NASDAQ:AGEN) reported earnings of -$0.01 per share for Q2 2026, missing the consensus estimate of $0.05. The report was announced on Friday, August 7, 2026. What was Agenus' revenue for Q2 2026? Agenus reported revenue of $34.52 million for Q2 2026, against a consensus estimate of $34.00 million. When is Agenus' next earnings date? Agenus' next earnings date is estimated for Monday, November 9, 2026. MarketBeat tracks confirmed and estimated earnings dates for Agenus on the company's earnings history page. Agenus Earnings HeadlinesAgenus to Participate in Chardan’s 10th Annual Healthcare Investor ConferenceOctober 9, 2026 | finance.yahoo.comAgenus to Participate in Chardan's 10th Annual Healthcare Investor ConferenceOctober 9, 2026 | businesswire.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing. | Profits Run (Ad)Agenus Gets Armenia Approval for Botensilimab-Balstilimab CombinationOctober 8, 2026 | finance.yahoo.comArmenia Grants First Marketing Authorizations for Agenus' BOT+BAL in Previously Treated MSS Metastatic Colorectal CancerOctober 8, 2026 | businesswire.comArmenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal CancerOctober 8, 2026 | financialpost.comFSee More Agenus Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Agenus? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Agenus and other key companies, straight to your email. Email Address About AgenusAgenus (NASDAQ:AGEN) (NASDAQ: AGEN) is a biotechnology company focused on developing immunotherapies for the treatment of cancer. The company’s research programs are designed to activate and strengthen the immune system’s ability to recognize and attack tumors, with an emphasis on therapies that may be used alone or in combination. Agenus’ pipeline includes botensilimab, an investigational Fc-enhanced CTLA-4 antibody, and balstilimab, an investigational PD-1 inhibitor. The company has studied these therapies in combination across several solid-tumor indications, including colorectal cancer and other advanced cancers. Agenus also develops additional immune checkpoint inhibitors, bispecific antibodies and cancer vaccine technologies intended to address different aspects of the tumor microenvironment. The company was founded in 1994 as Antigenics and adopted the Agenus name in 2011. Headquartered in Lexington, Massachusetts, Agenus conducts research and clinical development activities through operations and collaborations supporting programs in the United States and internationally. Garo H. Armen, Ph.D., is the company’s co-founder and chief executive officer.View Agenus ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
